Galvez hurt by COVID-19 vaccine overpricing claims

Vaccine czar Carlito Jr. opened up Thursday that he got hurt over the allegations against him regarding the claims in the overpricing of .

During the Laging Handa press briefing, Galvez was asked to react to the call of Akbayan Chair Emeritus Loretta Ann “Etta” Rosales for him to step down over speculations surrounding the COVID-19 deals.

Galvez said he respected Rosales’ opinion but noted she should not judge because she does not know the details of negotiations between the national government and the vaccine suppliers.

“Ginagalang ko po ‘yung ano po ni Ma’am Etta Rosales kasi magkakilala naman po kami pero dapat hindi muna siya mang-judge kasi ‘yung lahat po ng vaccine na nabili po natin ay talaga pong binigay po at cost, ang guidance po ng WHO [World Health Organization] sa mga manufacturer ay wala pong tinatawag na commercialization, no profit, magkaroon po ng equitable access… ‘yun po ay kasunduan lahat ng manufacturers that they will provide access to poor countries like us,” he said.

(I respect what Ma’am Etta Rosales said because we know each other, but she should not judge first because all the vaccines we bought are really given at a cost. The guidance to manufacturers is there should be no commercialization, no profit. All will have equitable access … that is the agreement of all manufacturers that they will provide access to poor countries like us.)

Galvez hurt by COVID-19 vaccine overpricing claims

“Ginagalang ko po ‘yung opinyon ninyo pero minsan nakakasakit po ng damdamin, wala po kayong alam sa negosasyon, napakahirap po ng negosasyon na ginagawa namin. Talagang ang ginagawa po namin ay binabagsak po namin ang presyo,” he added.

Galvez said the could lose 148 million doses of COVID-19 vaccines it has secured if he violates the confidentiality disclosure agreements he signed with the pharmaceutical companies.
Senate President Vicente Sotto III said he already saw the documents showing that the COVID-19 vaccine negotiations indeed involved non-disclosure agreements.